Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.
US8334290B2
申请人:——
公开号:US8334290B2
公开(公告)日:2012-12-18
[EN] CETP INHIBITORS<br/>[FR] INHIBITEURS DE LA CETP
申请人:MERCK & CO INC
公开号:WO2007070173A2
公开(公告)日:2007-06-21
[EN] Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. I [FR] La présente invention concerne des composés de la formule I, y compris des sels pharmaceutiquement acceptables des composés, qui sont des inhibiteurs de la CETP et qui sont utiles pour augmenter le cholestérol HDL, réduire le cholestérol LDL et traiter ou prévenir l'athérosclérose. I
[EN] CYCLIC DINUCLEOTIDE STING AGONISTS TETHERED TO A PD-1 OR CTLA-4 ANTIBODIES<br/>[FR] AGONISTES DE STING DINUCLÉOTIDIQUES CYCLIQUES ATTACHÉS À UN PD-1 OU À DES ANTICORPS CTLA-4
申请人:SPEROVIE BIOSCIENCES INC
公开号:WO2021046426A1
公开(公告)日:2021-03-11
Disclosed are antibody-drug conjugates and compositions thereof for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.